ATB Therapeutics develops targeted antibody therapies using its proprietary antibody payload technology to treat hematological malignancies and autoimmune diseases. The company addresses the need for effective treatments in oncology and autoimmune disorders by leveraging a plant-based manufacturing platform to enhance therapeutic delivery.
Funding
$60.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELMVFounders
Product
Problem
Current antibody therapies for hematological malignancies and autoimmune diseases often face challenges in effectively targeting diseased cells and overcoming resistance mechanisms, limiting their therapeutic potential. Traditional manufacturing processes can also be inefficient and costly.
Solution
ATB Therapeutics is developing a novel class of targeted antibody therapies, called atbodies, designed to improve efficacy and broaden the therapeutic window in oncology and autoimmune disorders. The atbody format offers a novel mechanism of action to avoid major cancer cell resistance. ATB Therapeutics leverages its proprietary atbiofarm technology, a versatile plant-based manufacturing platform, to enable single-step production of atbodies. This platform aims to enhance therapeutic delivery and reduce manufacturing costs.
Target Audience
The primary target audience includes patients with hematological malignancies and autoimmune diseases, as well as clinicians seeking more effective and targeted treatment options.
Features
- atbody format designed for improved targeting and therapeutic window
- Novel mechanism of action to overcome cancer cell resistance
- Proprietary atbiofarm plant-based manufacturing platform
- Single-step manufacturing process for efficient production
- Pipeline expansion into solid tumors